BMO Considers Recent Sales Data on Arena's Belviq; Merck Reports FDA Acceptance of NDA for Investigational Fertility Treatment Print E-mail
By Staff and Wire Reports   
Monday, 09 September 2013 20:04
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 9, 2013.

Investors in shares of Arena Pharma (NASDAQ: ARNA) are responding to several news items Monday. The stock last traded at $6.30, down more than 1.5 percent from Friday's closing price.

In addition to an earlier Seeking Alpha article evaluating the company's Belviq sales after three months, traders are also digesting a research note from BMO's Jim Birchenough.

Birchenough said 13-week prescriptions from Belviq showed 0.2 percent week-over-week growth. For the week ended Aug. 30th, the BMO analyst said total scrips were 3,849. Birchenough compared these figures to data on VIVUS's (NASDAQ: VVUS) Qsymia which showed units of 1,457 over the same duration.

Birchenough iterated he would suggest investors wait on the sidelines regarding Arena.

BMO maintains a Market Perform rating and $8 price target on shares of Arena.


Merck (NYSE: MRK)
, known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology.

If approved, corifollitropin alfa would be the first sustained follicular stimulant for use in a fertility treatment regimen.

Also Monday:

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR)
, a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the company has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide for the treatment of homozygous familial hypercholesterolemia (HoFH).

AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG)
today announced that Barbara Deptula, former executive vice president and chief corporate development officer of Shire plc, has been elected to AMAG's Board of Directors, effective September 6, 2013.

Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it's President & CEO Gerald Commissiong will make a corporate presentation at the 15th Annual Rodman & Renshaw Global Investor Conference in New York City on September 10th, 2013, sponsored by H.C. Wainwright & Co., LLC. announces that Arrayit Corporation (OTC: ARYC) has been approached, through their financial advisor, who is a major shareholder in the company, by an overseas bank, and 3 mid-level investment banking houses, to help Arrayit raise up to $10 million in funds, either through a secured loan, or a convertible bond issue, with the conversion above 100% of the current stock price.

Baxter International Inc. (NYSE:BAX)
announced today that its Board of Directors has elected Todd S. Young as treasurer and a corporate officer of the company.

, a biopharmaceutical development company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of acute myeloid leukemia (AML).

CEL-SCI Corporation (NYSE: CVM)
announced today that following an audit of its Multikine® manufacturing plant and laboratories by a European Union (EU) Qualified Person (QP), the CEL-SCI facilities were found to be in a high level of compliance with the Good Manufacturing Practices (GMP) Directives of the EU and the International Conference on Harmonization (ICH).

Charles River Laboratories International, Inc. (NYSE: CRL)
announced today that it will present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10th, at 9:10 a.m. EDT.

InspireMD, Inc. (NYSE MKT: NSPR)
, a leader in embolic protection stents, announced today that it will release its financial results for the fiscal year ended June 30, 2013 on Tuesday, September 17, 2013.  

International Stem Cell Corporation (OTCQB: ISCO)
, a California-based biotechnology company developing novel stem cell-based therapies, announced today further progress in its Parkinson's disease program with a recently held key opinion leader meeting facilitated by the study's principal investigator, Dr. Mark Stacy of Duke Medicine.

Magellan Health Services Inc. (NASDAQ:MGLN)
today announced that it has entered into an agreement to acquire Partners Rx®, a privately held, full-service commercial pharmacy benefits management company (PBM) with a strong focus on health plans and self-funded employers, sold primarily through third party administrators (TPAs), consultants and brokers.

Merck (NYSE:MRK)
, known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).

Meridian Bioscience, Inc. (NASDAQ: VIVO)
today provided the financial community with guidance regarding the Company’s fiscal 2014 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2014, management expects net sales to be in the range of $203 to $208 million and per share diluted earnings to be between $0.98 and $1.03.

MMRGlobal, Inc. (OTCQB: MMRF)
, a leading provider of Personal Health Records and MMRPro document management and imaging systems for healthcare professionals, today announced that the Company is offering a PHR for horses targeted to the multi-billion dollar equine industry.

Omeros Corporation (NASDAQ: OMER)
, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Stifel Healthcare Conference 2013 in Boston, Massachusetts this week.

Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ: ONCY)
today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at Baird's 2013 Healthcare Conference on Tuesday September 10th, 2013 at 8:30 a.m. ET.The conference will take place on September 10th and 11th in New York, NY at the New York Palace.

PDL BioPharma, Inc. (NASDAQ: PDLI)
today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase.

PharmAthene, Inc. (NYSE MKT: PIP)
announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company.

Rite Aid Corporation (NYSE:RAD)
announced today a set of comprehensive resources to help customers better understand the Affordable Care Act and to provide them with information they can use to help them make the best health insurance choices for themselves and their families.

Rosetta Genomics Ltd. (NASDAQ: ROSG)
, a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's Cancer Origin Test™.

Simulations Plus, Inc. (NASDAQ: SLP)
, a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fourth fiscal quarter and fiscal year 2013, ended August 31, 2013 (4QFY13).

StemCells, Inc. (Nasdaq:STEM)
today announced the publication of a comprehensive overview describing the therapeutic potential and results from early clinical trials of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells).

Skyline Medical Inc. (OTCQB: SKLN)
, formerly BioDrain Medical, producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain surgical fluid disposal, today announced that Advanced Orthopaedics, a privately held orthopedic practice based in Richmond, Va., has purchased three STREAMWAY System units to be installed in multiple surgical suits.

TG Therapeutics, Inc. (Nasdaq:TGTX)
, an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced the presentation of a pre-clinical poster on TGR-1202 at the 15th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) which is being held in Cologne, Germany.

ViroPharma Incorporated (Nasdaq: VPHM)
today announced that the company will present at the Stifel Nicolaus 2013 Healthcare Conference at 8:35 AM ET on Wednesday September 11, 2013.

Vision-Sciences, Inc. (Nasdaq:VSCI)
, a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced positive results from a three-month evaluation completed in 2012 by the British Army at Camp Bastion, a deployed field hospital in Afghanistan.

Theranos, Inc. and Walgreens (NYSE: WAG) (Nasdaq: WAG)
today announced a long-term partnership to bring access to Theranos’ new lab testing service through Walgreens pharmacies nationwide.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus